Eureka Therapeutics to Present New Clinical Data of anti-CD19 ARTEMIS™ 3.0 T-cell Therapy at 2019 ASH Annual Meeting
Emeryville, California, December 3, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new